Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neural TherapeuticsXCNQ:NURL PB Ratio is 2.50 as of Jul. 26, 2026. The stock has 1 warning sign investors should review. Among 1,231 Biotechnology companies, Neural Therapeutics ranks better than 54.1% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Neural Therapeutics PB Ratio Related Terms
Neural Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Neural Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XCNQ:NURL vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Neural Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neural Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neural Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Neural Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Neural Therapeutics (XCNQ:NURL) has a PB Ratio of 2.50 as of Jul. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Neural Therapeutics and its competitors. According to the industry distribution chart, Neural Therapeutics ranks #565 out of 1231 companies in the Biotechnology industry, placing it in the top 45.9%.
Is Neural Therapeutics' PB Ratio too high?
Neural Therapeutics' current PB Ratio is 2.50. The Biotechnology industry median PB Ratio is 2.77. Neural Therapeutics' value of 2.50 is 9.7% below this industry median. Based on the distribution chart, Neural Therapeutics ranks #565 out of 1231 companies in the Biotechnology industry, which is above the industry midpoint.
How does Neural Therapeutics' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neural Therapeutics ranks #565 out of 1231 companies for PB Ratio. This puts Neural Therapeutics in the upper half of its industry. The industry median PB Ratio is 2.77. Neural Therapeutics' value of 2.50 is 9.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.77, based on 1,231 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neural Therapeutics's current PB Ratio of 2.50 is 9.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Neural Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neural Therapeutics's current PB Ratio is 2.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neural Therapeutics stock overvalued right now?
Neural Therapeutics (XCNQ:NURL) has a current PB Ratio of 2.50. The current PB Ratio is 2.50 and 9.7% below the Biotechnology industry median of 2.77. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Neural Therapeutics (XCNQ:NURL), the current PB Ratio is 2.50 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Neural Therapeutics Inc is a wholly-owned subsidiary of High Fusion focused on ethnobotanical drug discovery and development company. Neural Therapeutics is focused on developing products and conducting research on the psychoactive cacti plants with the primary objective to find where the historical use in traditional medicine proves to be effective and capitalizing on the opportunities that can be applied in modern medical and natural health products markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XCNQ:NURL has been successfully added to your 
